The sequence of therapies like bispecifics and CAR-T critically impacts future options and outcomes. This necessitates early, strategic collaboration between community oncologists and academic centers to plan a patient's entire treatment journey, not just the next immediate step.

Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

In relapsed/refractory DLBCL, the timing of relapse is a critical factor in determining the next line of therapy. Patients who relapse within 12 months are preferred candidates for CAR-T therapy. Those relapsing after 12 months may first undergo salvage chemotherapy followed by an autologous stem cell transplant if they respond.

While scientifically novel, the primary advantage of in vivo CAR-T therapy is its potential to overcome the significant logistical barriers of traditional CAR-T. By simplifying the process to a single injection, it could democratize access for patients far from specialized academic medical centers.

Unlike autologous transplant, CAR T-cell therapy does not have strict age or organ function cutoffs. Patients over 75, or with conditions like an ejection fraction of 40%, can be eligible. The key pre-treatment goal is disease stability, not a deep response, making it accessible to a wider, less fit patient population.

Clinical trials for second-line DLBCL used a 12-month relapse cutoff for eligibility, but this shouldn't be interpreted rigidly in practice. A patient relapsing at 13 months is biologically similar to one at 11 months and should still be strongly considered for CAR T-cell therapy over salvage chemotherapy and transplant.

The argument against using certain frontline therapies for fear of compromising future CAR-T eligibility is tempered by a stark reality: only 5% of eligible US patients actually receive CAR-T. This logistical and access bottleneck means that optimizing immediate, available treatments is paramount for the vast majority of patients.

Experts advise referring patients to CAR T centers upon diagnosis, not when they need the therapy. This isn't for a "second opinion" but to establish a collaborative relationship early. This facilitates seamless access and planning when CAR T becomes necessary later.

The TRANSFORM study quantifies the critical importance of therapy timing. DLBCL patients receiving Liso-cel CAR-T as a second-line treatment had a 95% two-year overall survival, which dropped significantly to 78% for patients who received it third-line after crossover from the standard-of-care arm.